<DOC>
	<DOCNO>NCT01596374</DOCNO>
	<brief_summary>Alterations involve ROS ( v-ros UR2 sarcoma virus oncogene homolog 1 ) gene mutation , overexpression gene rearrangement implicate carcinogenesis demonstrate relevant target ALK inhibitor . While emerge report demonstrate role ROS rearrangement non-small cell lung cancer cholangiocarcinoma , functional significance ROS dysregulation solid tumor remain largely unstudied . The investigator aim : ( 1 ) To characterize frequency ROS gene fusion , ROS protein overexpression ROS gene mutation cell line tumor patient hepatocellular carcinoma , colorectal , gastric , breast , ovarian , cholangiocarcinoma non-small cell lung cancer , ( 2 ) To identify novel ROS gene variant human solid tumor harbor ROS aberration use next generation sequencing ( NGS ) , ( 3 ) To determine functional relevance novel ROS gene variant identify NGS , ( 4 ) To characterize sensitivity cell functionally relevant ROS aberration use ROS tyrosine kinase inhibitor . ROS fusion protein overexpression screen panel cell line primary tumor use Fluorescence In-situ Hybridization immunohistochemistry respectively . Targeted next-generation sequencing apply identify ROS variant match cancer type demonstrate high level gene fusion protein overexpression . Functional characterization novel ROS variant perform silence ( shRNA ) overexpressing candidate cell line respective ROS mutations/fusions , evaluate effect biological function include cell proliferation , migration , invasion apoptosis , well sensitivity ROS/ALK inhibitor . The investigator anticipate finding study improve investigator understand aberrant ROS signal expand group cancer type , potentially identify large group cancer patient benefit ROS target therapy . Further insight role ROS receptor tyrosine kinase confirm therapeutic target human solid tumor hence expand indication crizotinib dual ALK/ ROS inhibitor . Furthermore , give rarity ROS fusion receptor tyrosine kinase report cancer , define epidemiology ROS aberration unreported cancer harbor ROS pathway activation essential properly design future clinical trial ROS inhibitor . The validation ROS receptor tyrosine kinase also provide new therapeutic target treatment cancer expand role novel target agent . Findings study investigator knowledge oncogenic function ROS application ROS inhibitor extend group solid tumor .</brief_summary>
	<brief_title>Clinical Relevance ROS ( V-ros UR2 Sarcoma Virus Oncogene Homolog ) Aberrations Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Patients cancer</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>